25 related articles for article (PubMed ID: 38440976)
1. Erlotinib complexation with randomly methylated
Erdoğar N; Akkın S; Varan G; Bilensoy E
Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
3. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid.
Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S
Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
[TBL] [Abstract][Full Text] [Related]
5. Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Chan CY; Hong SC; Chang CM; Chen YH; Liao PC; Huang CY
Cells; 2023 Jan; 12(1):. PubMed ID: 36611972
[TBL] [Abstract][Full Text] [Related]
6. Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma
Mangla B; Mittal P; Kumar P; Javed S; Ahsan W; Aggarwal G
Nanomedicine (Lond); 2024 Apr; 19(10):855-874. PubMed ID: 38440976
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
8. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
9. Intraductal delivery of nanocarriers for ductal carcinoma
Pandey M; Wen PX; Ning GM; Xing GJ; Wei LM; Kumar D; Mayuren J; Candasamy M; Gorain B; Jain N; Gupta G; Dua K
Nanomedicine (Lond); 2022 Oct; 17(24):1871-1889. PubMed ID: 36695306
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials for Ductal Carcinoma In Situ of the Breast.
Han MS; Khan SA
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):293-301. PubMed ID: 30206737
[TBL] [Abstract][Full Text] [Related]
11. Current approach and future perspective for ductal carcinoma in situ of the breast.
Kanbayashi C; Iwata H
Jpn J Clin Oncol; 2017 Aug; 47(8):671-677. PubMed ID: 28486668
[TBL] [Abstract][Full Text] [Related]
12. Surgical treatment of ductal carcinoma in situ of the breast. 10- to 20-year follow-up.
Simpson T; Thirlby RC; Dail DH
Arch Surg; 1992 Apr; 127(4):468-72. PubMed ID: 1313671
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
